CN107001279B - Cxcr7受体调节剂 - Google Patents

Cxcr7受体调节剂 Download PDF

Info

Publication number
CN107001279B
CN107001279B CN201580064998.4A CN201580064998A CN107001279B CN 107001279 B CN107001279 B CN 107001279B CN 201580064998 A CN201580064998 A CN 201580064998A CN 107001279 B CN107001279 B CN 107001279B
Authority
CN
China
Prior art keywords
ethyl
tetrahydro
benzo
acetamide
ylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580064998.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN107001279A (zh
Inventor
菲利普·盖里
弗朗索瓦·勒亨布利
朱利安·波蒂埃
赫尔维·西恩德特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of CN107001279A publication Critical patent/CN107001279A/zh
Application granted granted Critical
Publication of CN107001279B publication Critical patent/CN107001279B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN201580064998.4A 2014-12-01 2015-11-30 Cxcr7受体调节剂 Expired - Fee Related CN107001279B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2014076126 2014-12-01
EPPCT/EP2014/076126 2014-12-01
PCT/EP2015/078058 WO2016087370A1 (en) 2014-12-01 2015-11-30 Cxcr7 receptor modulators

Publications (2)

Publication Number Publication Date
CN107001279A CN107001279A (zh) 2017-08-01
CN107001279B true CN107001279B (zh) 2020-10-20

Family

ID=54705645

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580064998.4A Expired - Fee Related CN107001279B (zh) 2014-12-01 2015-11-30 Cxcr7受体调节剂

Country Status (7)

Country Link
US (1) US10202368B2 (https=)
EP (1) EP3227263B1 (https=)
JP (1) JP6582056B2 (https=)
CN (1) CN107001279B (https=)
CA (1) CA2963447A1 (https=)
ES (1) ES2732437T3 (https=)
WO (1) WO2016087370A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA028604B1 (ru) 2013-05-30 2017-12-29 Идорсиа Фармасьютиклз Лтд. Модуляторы рецептора cxcr7
HRP20230313T1 (hr) * 2016-07-28 2023-05-12 Idorsia Pharmaceuticals Ltd Modulatori receptora cxcr7 piperidina
CN112266368B (zh) * 2017-11-15 2024-03-19 中山光禾医疗科技有限公司 光交联水凝胶材料的制备、原料、产品及应用
KR102502046B1 (ko) * 2018-01-26 2023-02-20 이도르시아 파마슈티컬스 리미티드 Cxcr7 수용체 작동제 (3s,4s)-1-시클로프로필메틸-4-｛[5-(2,4-디플루오로-페닐)-이속사졸-3-카르보닐]-아미노｝-피페리딘-3-카르복실산 (1-피리미딘-2-일-시클로프로필)-아미드의 결정질 형태
WO2020207263A1 (zh) * 2019-04-08 2020-10-15 四川科伦博泰生物医药股份有限公司 苯并咪唑化合物、其制备方法及其用途
MX2023012365A (es) * 2021-04-19 2023-11-27 Chemocentryx Inc Azetidinil-acetamidas como inhibidores de cxcr7.
CN120202196A (zh) 2022-11-16 2025-06-24 巴斯夫欧洲公司 作为杀真菌剂的取代的苯并二氮杂䓬类
WO2024104822A1 (en) 2022-11-16 2024-05-23 Basf Se Substituted tetrahydrobenzodiazepine as fungicides
CN120202195A (zh) 2022-11-16 2025-06-24 巴斯夫欧洲公司 作为杀真菌剂的取代的苯并二氮杂䓬类

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639748A (en) * 1991-08-05 1997-06-17 Smithkline Beecham Corporation 6,9-disubstituted benzazepines having α-adrenoceptor blocking activity
JP2002371042A (ja) * 2001-06-12 2002-12-26 Takeda Chem Ind Ltd ジアミン化合物、その製造法および用途
CN101535276A (zh) * 2006-10-23 2009-09-16 赛福伦公司 作为ALK和c-MET抑制剂的2，4-二氨基嘧啶稠合双环衍生物
CN101945863A (zh) * 2007-12-21 2011-01-12 葛兰素集团有限公司 对鞘氨醇-1-磷酸(s1p)具有活性的*二唑衍生物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9116824D0 (en) * 1991-08-05 1991-09-18 Smithkline Beecham Corp Chemical compounds
IL137720A0 (en) 1998-02-18 2001-10-31 Neurosearch As Compounds and their use as positive ampa receptor modulators
WO2002046164A1 (en) 2000-12-07 2002-06-13 Astrazeneca Ab Therapeutic compounds
ATE427933T1 (de) * 2002-12-20 2009-04-15 Chemocentryx Inc Inhibitoren der bindungder chemokine i-tac bzw. sdf-1 an den ccxckr2-rezeptor
EP1575874B1 (en) 2002-12-23 2010-09-08 Council of Scientific and Industrial Research Process for preparing hydrotalcite and brucite type posite charged layers
US20050192272A1 (en) * 2003-12-22 2005-09-01 Garland Marshall Substituted benzodiazepines as inhibitors of the chemokine receptor CXCR4
DE602006018057D1 (de) 2005-11-10 2010-12-16 Chemocentryx Inc Substituierte chinolone und verwendungsverfahren
EP2069347A2 (en) 2006-09-27 2009-06-17 Merck & Co., Inc. Novel inhibitors of beta-lactamase
US20100331298A1 (en) 2007-12-10 2010-12-30 Cytopathfinder, Inc. Carboxamide Compounds and Their Use
US8748623B2 (en) * 2009-02-17 2014-06-10 Syntrix Biosystems, Inc. Pyridinecarboxamides as CXCR2 modulators
AR091516A1 (es) 2012-06-22 2015-02-11 Actelion Pharmaceuticals Ltd Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida
EA028604B1 (ru) 2013-05-30 2017-12-29 Идорсиа Фармасьютиклз Лтд. Модуляторы рецептора cxcr7

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639748A (en) * 1991-08-05 1997-06-17 Smithkline Beecham Corporation 6,9-disubstituted benzazepines having α-adrenoceptor blocking activity
JP2002371042A (ja) * 2001-06-12 2002-12-26 Takeda Chem Ind Ltd ジアミン化合物、その製造法および用途
CN101535276A (zh) * 2006-10-23 2009-09-16 赛福伦公司 作为ALK和c-MET抑制剂的2，4-二氨基嘧啶稠合双环衍生物
CN101945863A (zh) * 2007-12-21 2011-01-12 葛兰素集团有限公司 对鞘氨醇-1-磷酸(s1p)具有活性的*二唑衍生物

Also Published As

Publication number Publication date
ES2732437T3 (es) 2019-11-22
EP3227263B1 (en) 2019-04-10
CN107001279A (zh) 2017-08-01
US10202368B2 (en) 2019-02-12
CA2963447A1 (en) 2016-06-09
WO2016087370A1 (en) 2016-06-09
US20170327493A1 (en) 2017-11-16
JP2017535618A (ja) 2017-11-30
EP3227263A1 (en) 2017-10-11
JP6582056B2 (ja) 2019-09-25

Similar Documents

Publication Publication Date Title
CN107001279B (zh) Cxcr7受体调节剂
JP7675777B2 (ja) 免疫調節剤としての複素環式化合物
CN105683188B (zh) 作为fgfr4抑制剂的稠环二环吡啶基衍生物
TWI743401B (zh) 吲哚甲醯胺化合物
CN110563717B (zh) 哌啶cxcr7受体调节剂
CN104470523B (zh) 基于咪唑并[1,2‑b]哒嗪的化合物、包含它们的组合物及其使用方法
KR102228764B1 (ko) 키나제 억제제로서의 헤테로시클릭 아미드
CN105008360B (zh) 治疗活性的吡唑并嘧啶衍生物
CN111050765B (zh) 螺环化合物及其制造和使用方法
JP6800885B2 (ja) イミダゾピラジン及びピラゾロピリミジン、並びにａｍｐａ受容体調節物質としてのこれらの使用
KR20190091537A (ko) C-kit 억제제로서의 아미노티아졸 화합물
CN107295799A (zh) Parg抑制化合物
RS60468B1 (sr) Nova jedinjenja
CN105814048A (zh) 作为tnf活性调节剂的稠合三环苯并咪唑衍生物
AU2007207671A1 (en) Compounds for the treatment of inflammatory disorders
KR20100082807A (ko) 오렉신 수용체 길항제로서의 헤테로아릴 유도체
CN106459088A (zh) 2‑氨基‑6‑甲基‑4，4a，5，6‑四氢吡喃并[3，4‑d][1，3]噻嗪‑8a(8H)‑基‑1，3‑噻唑‑4‑基酰胺
ES2645470T3 (es) Moduladores del receptor cxcr7
EP3359531A1 (en) 2-oxo-1,2-dihydropyridine-3,5-dicarboxamide compounds as bromodomain inhibitors
TW201602116A (zh) 作為β－分泌酶抑制劑之橋接二環胺基噻嗪二氧化物化合物及其使用方法
CA3234693A1 (en) Novel modulators of ehmt1 and ehmt2 and therapeutic use thereof
CN110225912A (zh) Gsk-3抑制剂
EP4725942A1 (en) Compounds active on cyclin d1 pathway and their use
WO2023208124A1 (zh) 哌啶甲酰胺氮杂茚满类衍生物及其制备方法和用途
WO2024240256A1 (zh) 作为激酶抑制剂的多环化合物及其制备方法和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20171012

Address after: Swiss A Skei Weil

Applicant after: ACTELION PHARMACEUTICALS LTD.

Address before: Swiss A Skei Weil

Applicant before: Actelion Pharmaceuticals Ltd.

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20201020